Xinrui Pharmaceutical (06108) issued an announcement. On May 28, 2024, China Xinrui (a wholly-owned subsidiary of the company...
Zhitong Finance App News, Xinrui Pharmaceutical (06108) announced that on May 28, 2024, China Xinrui (a wholly-owned subsidiary of the company, as an investor) signed a cornerstone investment agreement with Jiangxi Yimai Sunshine Group, CITIC Securities (Hong Kong) Co., Ltd. and CITIC Lyon Securities Co., Ltd. Based on this, China Xinrui has agreed to subscribe for investors' shares at the sale price. The total investment in investors' shares is HK$12 million.
According to the announcement, Cornerstone Investment provides the Group with an excellent opportunity to invest in medical imaging equipment and services. Jiangxi Yimai Sunshine Group and its subsidiaries are mainly engaged in providing medical imaging services, imaging solution services and Yimai cloud services in China. In view of the prospects and business prospects of Jiangxi Yimai Sunshine Group, the directors believe that the investment in Jiangxi Yimai Sunshine Group is in line with the Group's long-term business strategy of achieving diversified and continuous development and bringing return on investment to shareholders.